Pfizer Inc.
Discovers, develops, manufactures and markets a broad portfolio of biopharmaceutical products including vaccines, oncology therapies, and treatments for cardiovascular, inflammation, rare disease and infectious conditions.
As of Jul 17, 2026
Executive summary
Pfizer is a major pharmaceutical company trading on the NYSE with a market capitalisation of $143 billion. The stock is showing neutral technical bias at $25.05, down 0.4% today, though it has returned 8.9% over the past year despite a 3.8% decline in the last month.
Price history
As of Jul 17, 2026
Performance
-0.36%
+3.64%
-3.80%
-6.45%
+3.98%
+8.90%
As of Jul 17, 2026
Technical indicators
- 53.8
- 0.16Bullish
- 50: 25.25 · 200: 25.34Bearish
- $23.62 / $24.57
Technical Bias
Pfizer's technical setup shows mixed signals across its indicators: momentum measured by MACD is bullish, but the relationship between its 50-day and 200-day moving averages suggests bearish pressure, whilst RSI sits neutrally in the middle ground. This derived technical read reflects the split positioning, with price currently trading above both moving averages yet facing resistance at $24.57 and support below at $23.62.
A transparent read of the indicators below — not a prediction or recommendation.
As of Jul 17, 2026
Fundamentals
- $143B
- 18.9
- $1.33
- 11.83%
- +5.4%
- $9.08B
- 0.31
- $21.97 – $28.28
- 6.93%
- Jul 24, 2026
- Aug 4, 2026 (16 days)
As of Jul 18, 2026
Upcoming catalysts
- Ex-dividend date
- Earnings report
As of Jul 18, 2026
Latest news
As of Jul 18, 2026
Short-term outlook
Pfizer's technical picture is mixed: MACD points to bullish momentum while RSI sits neutral and price hovers just below both its 50-day and 200-day averages, a bearish sign near-term. With shares down 3.8% over the past month, the stock is testing resistance at $24.57, and a break above could open room to run, while $23.62 remains the key support to watch. No earnings catalyst until August 2026 keeps the near-term picture technically driven.
Medium-term outlook
Pfizer's revenue is growing at a modest 5.4% year-on-year, with a profit margin of 11.8% and a price-to-earnings ratio of 18.9, suggesting the stock isn't priced for aggressive growth. The dividend yield of 6.9% stands out and may appeal to income-focused investors. With the technical picture reading neutral, the next few quarters may hinge more on fundamentals than on short-term price momentum.
Key risks
- A low beta of 0.31 suggests Pfizer shares tend to be less reactive to broad market swings, but that also means limited upside momentum if sentiment turns bullish across healthcare.
- Profit margin of 11.8% is relatively modest for a large pharmaceutical company, leaving less cushion if costs rise or pricing pressure increases.
- Competitive dynamics in areas like HIV treatment show rivals actively pushing forward, a reminder that Pfizer operates in crowded therapeutic categories where market share can shift.
- The stock trading at $25.05, well off its 52-week high of $28.28, points to renewed weakness that would need clear catalysts to reverse.
About Pfizer Inc.
Pfizer Inc. (NYSE: PFE) is one of the world's largest pharmaceutical companies, developing and manufacturing medicines and vaccines across a broad range of therapeutic areas. Sitting within the Healthcare sector under the Drug Manufacturers - General industry, Pfizer holds a market capitalisation of $143B, reflecting its scale and established position among global drugmakers. Its size gives it significant reach across research, manufacturing and distribution, supporting a wide portfolio that spans both branded treatments and vaccines.
Pfizer's key figures give a sense of how the market currently views the business. A price-to-earnings ratio of 18.9 shows how much investors are paying for each dollar of current earnings, offering a read on valuation relative to profitability. Meanwhile, a dividend yield of +6.9% highlights the company's emphasis on returning cash to shareholders, a factor often watched closely by income-focused investors weighing steady payouts against broader sector trends.
AI-assisted research for informational purposes only — not investment advice. Figures are sourced from third-party market data and may be delayed. Do your own research before trading. Your capital is at risk.